Beam Therapeutics Inc. (NASDAQ:BEAM) currently has a daily average trading volume of 954.03K but it saw 397012 shares traded on Wednesday. With a market cap of 3.25B USD, stock’s current market price of $45.70 came rising about 0.62 while comparing to the previous closing price of $45.42. In past 52 weeks, the stock remained buoying in the range of price level as high as $88.18 and as low as $27.77. In the recent trading on the day, stock has struck highest price mark of $47.47 while lowest mark touched by it was $45.34.
Taking a look at 20-day trading activity of Beam Therapeutics Inc. (BEAM) gives us an average price of $45.03, while its current price level is -48.17% below from 52-week high level whereas it is 64.57% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $47.31 while that of 200 days or SMA-200 reads an average of $50.96. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.09% during that period while stretching the period over a month that increases to 8.10%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 48.96 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BMO Capital Markets which initiated the stock as “Market Perform” in its note to investors issued on June 17, 2022, recommending a price target of $41 for it. Guggenheim also issued its recommendations for the stock as it initiated the price target for the stock is $130.
Over the week, BEAM’s stock price is moving -4.37% down while it is -2.23% when we observe its performance for the past one month. Year-to-date it is -42.65% down and over the past year, the stock is showing a downside performance of -44.70%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$1.02 beat the consensus estimate of -$1.08 for the same. For BEAM, analysts are forecasting an EPS-growth rate of 20.10% for current year and estimate for EPS growth in next year is -17.40%. In next quarter, company is expected to be making quarterly sales of $12.15 million as analysts are expecting the sales for current fiscal year at $44.06 million and seeing the company making $32.15 million in sales next year. Moreover, analysts are in estimates of $7.94 million for current-quarter revenue.
Currently, Beam Therapeutics Inc.’s total number of outstanding shares is 70.34M with 1.90% of that held by the insiders while 87.50% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -47.20% and return on equity (ROE) at -39.80%. Stock has a price to book (P/B) ratio of 4.50 while price to sale or P/S ratio amounts to 35.35. Its return on asset (ROA) is -22.20% on average.
A filing at the U.S. Securities and Exchange Commission revealed that ARK Innovation ETF came shrinking its share ownership by -1.26% in the Beam Therapeutics Inc. (BEAM) decreasing its stake to 8.76% with control over 78600.0 shares in the company. As per SEC documents, ARK Innovation ETF sought 6,159,696 of company’s common stock of worth $271.4 million as per recent closing price of the stock. ARK Innovation ETF is not the only institutional holder which restructured its stake in Beam Therapeutics Inc., as Vanguard Total Stock Market Index picked 2,010,380 shares of worth $88.58 million to bring its holdings to a total of 8557.0 shares. In the most recent quarter, ARK Genomic Revolution ETF came cutting its stake by -0.50% in the company and now holds 1.97 million or 2.80% of the company’s stake having worth of about 86.68 million.